Enrique Alvarez, MD, PhD
Affiliations: | Neurology | University of Colorado, Boulder, Boulder, CO, United States |
Area:
multiple sclerosis, biomarkersGoogle:
"Enrique Alvarez"Mean distance: 20.48 (cluster 46)
Parents
Sign in to add mentorAnne Haney Cross | post-doc | 2010-2013 | Washington University School of Medicine |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Longbrake EE, Hua LH, Mowry EM, et al. (2022) The CELLO trial: Protocol of a planned phase 4 study to assess the efficacy of Ocrelizumab in patients with radiologically isolated syndrome. Multiple Sclerosis and Related Disorders. 68: 104143 |
Ziemssen T, Arnold DL, Alvarez E, et al. (2022) Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials. Frontiers in Immunology. 13: 852563 |
Alvarez E, Nair KV, Hoyt BD, et al. (2021) Brain atrophy rates in patients with multiple sclerosis on long term natalizumab resembles healthy controls. Multiple Sclerosis and Related Disorders. 55: 103170 |
Vollmer TL, Cohen JA, Alvarez E, et al. (2020) Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. Multiple Sclerosis and Related Disorders. 46: 102454 |
Vollmer BL, Nair K, Sillau S, et al. (2020) Rituximab versus natalizumab, fingolimod, and dimethyl fumarate in multiple sclerosis treatment. Annals of Clinical and Translational Neurology |
Vollmer BL, Wallach AI, Corboy JR, et al. (2020) Serious safety events in rituximab-treated multiple sclerosis and related disorders. Annals of Clinical and Translational Neurology |
Almuklass AM, Capobianco RA, Feeney DF, et al. (2019) Sensory nerve stimulation causes an immediate improvement in motor function of persons with multiple sclerosis: A pilot study. Multiple Sclerosis and Related Disorders. 38: 101508 |
Vollmer B, Ontaneda D, Harris H, et al. (2019) Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. Journal of the Neurological Sciences. 407: 116498 |
Wolf AB, Ryerson LZ, Pandey K, et al. (2019) Rituximab-induced serum sickness in multiple sclerosis patients. Multiple Sclerosis and Related Disorders. 36: 101402 |
Lovett-Racke AE, Gormley M, Liu Y, et al. (2019) B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients. Journal of Neuroimmunology. 332: 187-197 |